Exabis Library
Welcome to the e-CCO Library!
P512: Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P513: Assessment of quality indicators in The Swedish Inflammatory Bowel Disease Registry (SWIBREG) for Crohn’s Disease treated with biological therapies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P513: Managing IBD patients on adalimumab based on trough levels and antibodies
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P513: Performance of a rapid test for adalimumab monitoring vs. conventional ELISA in a routine laboratory setting
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P513: Prospective study on patients' satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P513: Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P514 Does faecal diversion induce clinical response for Crohn’s disease of the colorectum?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P514: Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P514: Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small-molecule drugs in ulcerative colitis: A meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P514: Health Care Transition outcomes in inflammatory bowel disease: an international Delphi study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P514: Influence of the frequency of glucocorticosteroid therapy courses on the hormonal resistance in patients with ulcerative colitis.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P514: Optimising response to infliximab in the management of perianal Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P514: Serum levels of Klotho in inflammatory bowel disease: an exploratory study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P515 Comparability of upadacitinib pharmacokinetics in Japanese and non-Japanese subjects with ulcerative colitis with the extended-release formulation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P515: A 12-week tailored physical training program including dietary advice in children with Inflammatory Bowel Disease: a randomized crossover trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P515: Costs associated with the management of refractory complex perianal fistulas in patients with Crohn's disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P515: Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P515: Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapy
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM